Posted: 23 January
Innovative Australian biotech Noxopharm Limited announces the DARRT-2 Safety Steering Committee has reviewed safety data from the third cohort of patients from the dose escalation part of the DARRT-2 trial.
The DARRT-2 Phase 2 trial is evaluating Noxopharm’s clinical drug candidate Veyonda in combination with low-dose external beam radiotherapy with a focus on the treatment of prostate cancer.
The third cohort of patients was treated with a 1600 mg dose, which was found to be safe. This means that no further dose escalations will occur and the trial can soon progress into Part 2, which will evaluate efficacy signals while safety data continues to be collected. Pending some protocol requirements, Part 2 is expected to begin in late Q1 or early Q2 this year.
Noxopharm CEO Dr Gisela Mautner said: “This meeting marks a positive development in the progress of DARRT-2. We are proceeding according to schedule as we now wind down the first part of the trial and look to start focusing on efficacy in the very near future.
“As stated in the recent AGM, we are actively exploring ways to reduce patient numbers and costs while bringing forward efficacy data. And when results are meaningful, we will target data releases via high-profile conferences and peer-reviewed publications to maximise commercial potential.”
